FDA Approves Pembrolizumab for PD-L1+ Esophageal Cancer

July 31, 2019 – The FDA has approved pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (combined positive score [CPS] ≥10) as determined by an FDA-approved test, with disease progression after ≥1 prior line of systemic therapy. The approval is based on findings from the phase III KEYNOTE-181 and phase II KEYNOTE-180 trials, in which pembrolizumab led to … (leggi tutto)